Insider Selling Rush at High-Flying Stocks and Griffin's J&J Bet

애널리스트 | Mon Jul 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) | 6 sources

Executives at rapidly appreciating stocks executed 10b5-1 sales while Ken Griffin expanded his Johnson & Johnson stake.

Analysis

[Rapport Therapeutics] COO Cheryl Gault sold approximately $416K worth of company stock ^[1]

Sold 10
000 shares at $41.58 per share
Regular disposition under a 10b5-1 plan
Retained 149
914 shares (approximately $5.9M) after the sale
One-year stock price gain of 223.67%

[Aura Minerals] COO divested approximately $1.2M in shares ^[2]

Sold 19
010 shares as revenue surged 136% year-over-year
Executed under a 10b5-1 plan adopted March 20
2026
Retained 390
628 shares (approximately $25.57M)
Stock up approximately 124% since its July 2025 listing

[Vicor Corporation] CEO Patrizio Vinciarelli made a small $212K sale ^[3]

Sold 700 shares at $302.40 per share
Executed under a 10b5-1 plan adopted February 26
2026
Maintained a total of 8
514
515 shares after the sale
Revenue grew 20% on AI demand
with a one-year stock gain of approximately 500%

[Invesco] Executive Jeffrey Kupor disposed of 26,002 shares for tax withholding purposes ^[4]

Transaction value approximately $702K at $27.01 per share
Non-discretionary tax withholding tied to RSU vesting
Retained 125
818 shares directly (approximately $3.5M)
One-year total return of 63%

[Adaptive Biotechnologies] CSO Harlan Robins executed an $8.5M bulk sale ^[5]

Sold 386
240 shares at $22.01 per share
Executed under a 10b5-1 plan established March 13
2026
Retained 1
019
658 shares directly (approximately $21.61M)
One-year total return of 85%

[Ken Griffin / Johnson & Johnson] Citadel expanded its J&J position by 146% ^[6]

Q1 holdings increased to 1
930
976 shares
Portfolio weighting of 0.08%
held since 2017
Innovative Medicine revenue grew 11%
MedTech revenue grew 7%
28 platforms generating over $1 billion in revenue

Sources